While the majority of patients with psoriasis will be treated with topical agents, a significant
number will still require escalation to systemic therapy. The choice of systemic therapy will …

Background Patients with psoriasis who are treated with systemic and biologic therapies
may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that …

Psoriasis is a chronic inflammatory T cell–mediated condition that affects approximately 1%
of children. Of the risk factors, obesity is associated with higher frequency and severity of …

Hepatitis B virus reactivation after ustekinumab treatment: reply from authors Page 1 while
HbsAg is negative in the serum. Occult HBV infection is classified into two groups based on HBV …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

Biological therapies used in psoriasis treatment pose a risk of reactivation of hepatitis B virus
(HBV) infection. This risk occurs not only in patients with HB surface antigen (HBsAg)(+) but …

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the
world's population. Immunobiological medications are prescribed for certain patients with …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Discussion Ustekinumab is a fully human, monoclonal antibody that blocks interleukin (IL)-
12 and IL-23 via their common p40 protein subunit. 2 It is approved by the US Food and …

Reactivation of hepatitis B virus (HBV) following the use of TNF antagonists has been
reported and is a contraindication to use of these medications. Although the risk of …